Buprenorphine HCl, Injection, 0.3mg/mL, For Intramuscular or Intravenous Use, Rx Only, 1mL Single Dose Vial, (supplied in packages of 5 vials) Distributed by Par Pharmaceutical, Chestnut Ridge, NY 10977, NDC: 42023-179-05

Crystallization; identified as Buprenorphine free base

Recall #: D-0087-2024
Initiated: November 9, 2021

Compiled from official public sources by the publisher. · Updated September 2026

Par Sterile Products LLC recalled Buprenorphine HCl, Injection, 0.3mg/mL, For Intramuscular or Intravenous Use, Rx Only, 1m… - a moderate-severity action.

Buprenorphine HCl, Injection, 0.3mg/mL, For Intramuscular or Intravenous Use, Rx Only, 1m… was recalled by Par Sterile Products LLC in November 15, 2023. Reason: Crystallization; identified as Buprenorphine free base. Check the official notice for the remedy. Verify recall #D-0087-2024 with the FDA Drug before acting.

The recall

Par Sterile Products LLC issued this moderate-severity FDA Drug recall-Crystallization; identified as Buprenorphine free base.

Moderate
severity level: Class II
classification: November 15, 2023
reported

Sourced from official FDA Drug enforcement records. Verify recall #D-0087-2024 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

The number of affected units is not disclosed in the agency filing, which is common for drug and food recalls where lot-level tracking supersedes unit counts. Distribution scope (see Distribution below) directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

Within the same product category the archive holds 6 closely related recalls, 6 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Where this agency-classified recall sits among FDA Class I/II/III notices

Of 88,244 recalls with an agency hazard classification, 19,068 are high severity, 64,652 moderate, and 4,524 low. A further 16,179 CPSC/NHTSA recalls have no agency class and are excluded from this split. This recall is classified moderate severity.

Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.

Product description

Buprenorphine HCl, Injection, 0.3mg/mL, For Intramuscular or Intravenous Use, Rx Only, 1mL Single Dose Vial, (supplied in packages of 5 vials) Distributed by Par Pharmaceutical, Chestnut Ridge, NY 10977, NDC: 42023-179-05

Reason for recall

Crystallization; identified as Buprenorphine free base

Recall Profile

Structured summary of the FDA Drug recall record
Attribute	Value
Agency	U.S. Food and Drug Administration
Severity class	Moderate (Class II)
Status	Terminated
Recall number	D-0087-2024
Date reported	November 15, 2023
Date initiated	November 9, 2021
Recalling firm	Par Sterile Products LLC
Firm location	Rochester, MI
Affected scope	Not disclosed
Distribution	Nationwide USA

Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.

What to do with this recall

Match your product against the recall record, then act on the agency remedy.

Check the recall number (D-0087-2024) and product description against the item you own. Search the archive
Confirm the current status with FDA Drug before acting, recall details can be updated.
Follow the documented remedy (refund, replacement, repair, or disposal) rather than general advice. What to do next

This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled? ▼

Why was this product recalled? ▼

Crystallization; identified as Buprenorphine free base

Which agency issued this recall? ▼

This recall was issued by the FDA Drug on November 15, 2023. Severity: Moderate. Recall number: D-0087-2024.

Where was the recalled product distributed? ▼

Distribution: Nationwide USA.

Should I stop using a recalled medication or medical device? ▼

Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.

Nationwide recalls with similar severity or category timing

Drug and device notices outside this firm and state, matched by severity timing and product category.

Similar severity · nearest report date

Same archive severity grade (Moderate), closest by report date among other firms and states.

Montelukast Sodium Tablets, USP 10 mg, Rx… 2023-11-15 Extended Phenytoin Sodium Capsules, USP, … 2023-11-15 Clinical TREAT Antifungal Powder, Vanilla… 2023-11-15 Ranolazine Extended-Release Tablets 500mg… 2023-11-15

Similar Drugs & Medications · nearest report date

Same product category, closest by report date among other firms and states (deduped against the severity set).

Oxaydo (oxycodone HCl, USP) tablets, 7.5 … 2023-11-15 Oxybutynin Chloride Extended-Release Tabl… 2023-11-15 Oxybutynin Chloride Extended-Release Tabl… 2023-11-15 Oxybutynin Chloride Extended-Release Tabl… 2023-11-15

Compare this recall with Kian Pee Wan Capsules, 30-count bottles → · All Drugs & Medications recalls

This recall: FDA Drug, reported November 15, 2023. Severity classes follow each agency's own taxonomy; related-recall context is computed across the full archive.

Methodology · Corrections · Archive as of August 2026